Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging

Y. X.J. Wang, S. M. Hussain, G. P. Krestin

Research output: Contribution to journalArticle

1051 Citations (Scopus)

Abstract

Superparamagnetic iron oxide MR imaging contrast agents have been the subjects of extensive research over the past decade. The iron oxide particle size of these contrast agents varies widely, and influences their physicochemical and pharmacokinetic properties, and thus clinical application. Superparamagnetic agents enhance both T1 and T2/T2* relaxation. In most situations it is their significant capacity to reduce the T2/T2* relaxation time to be utilized. The T1 relaxivity can be improved (and the T2/T2* effect can be reduced) using small particles and T1-weighted imaging sequences. Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80-150 nm); SHU 555A (i.e. Resovist, mean diameter 60 nm)]. Smaller iron oxide particles are selected for lymph node imaging [AMI-227 (i.e. Sinerem and Combidex, diameter 20-40 nm)], bone marrow imaging (AMI-227), perfusion imaging [NC100150 (i.e. Clariscan, mean diameter 20 nm)] and MR angiography (NC100150). Even smaller monocrystalline iron oxide nanoparticles are under research for receptor-directed MR imaging and magnetically labeled cell probe MR imaging. Iron oxide particles for bowel contrast are coated with insoluble material, and all iron oxide particles for intravenous injection are biodegradable. Superparamagnetic agents open up an important field for research in MR imaging.

Original languageEnglish (US)
Pages (from-to)2319-2331
Number of pages13
JournalEuropean Radiology
Volume11
Issue number11
DOIs
StatePublished - Nov 20 2001

Fingerprint

Contrast Media
Research
Perfusion Imaging
Particle Size
Intravenous Injections
ferric oxide
ferumoxtran-10
Angiography
Spleen
Pharmacokinetics
Lymph Nodes
Bone Marrow
ferumoxides
Liver
ferumoxsil

Keywords

  • Contrast agent
  • Iron oxide
  • MR imaging
  • Superparamagnetism

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Superparamagnetic iron oxide contrast agents : Physicochemical characteristics and applications in MR imaging. / Wang, Y. X.J.; Hussain, S. M.; Krestin, G. P.

In: European Radiology, Vol. 11, No. 11, 20.11.2001, p. 2319-2331.

Research output: Contribution to journalArticle

Wang, Y. X.J. ; Hussain, S. M. ; Krestin, G. P. / Superparamagnetic iron oxide contrast agents : Physicochemical characteristics and applications in MR imaging. In: European Radiology. 2001 ; Vol. 11, No. 11. pp. 2319-2331.
@article{9480bd5f0b4042bfb7dc85fc367fd6c7,
title = "Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging",
abstract = "Superparamagnetic iron oxide MR imaging contrast agents have been the subjects of extensive research over the past decade. The iron oxide particle size of these contrast agents varies widely, and influences their physicochemical and pharmacokinetic properties, and thus clinical application. Superparamagnetic agents enhance both T1 and T2/T2* relaxation. In most situations it is their significant capacity to reduce the T2/T2* relaxation time to be utilized. The T1 relaxivity can be improved (and the T2/T2* effect can be reduced) using small particles and T1-weighted imaging sequences. Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80-150 nm); SHU 555A (i.e. Resovist, mean diameter 60 nm)]. Smaller iron oxide particles are selected for lymph node imaging [AMI-227 (i.e. Sinerem and Combidex, diameter 20-40 nm)], bone marrow imaging (AMI-227), perfusion imaging [NC100150 (i.e. Clariscan, mean diameter 20 nm)] and MR angiography (NC100150). Even smaller monocrystalline iron oxide nanoparticles are under research for receptor-directed MR imaging and magnetically labeled cell probe MR imaging. Iron oxide particles for bowel contrast are coated with insoluble material, and all iron oxide particles for intravenous injection are biodegradable. Superparamagnetic agents open up an important field for research in MR imaging.",
keywords = "Contrast agent, Iron oxide, MR imaging, Superparamagnetism",
author = "Wang, {Y. X.J.} and Hussain, {S. M.} and Krestin, {G. P.}",
year = "2001",
month = "11",
day = "20",
doi = "10.1007/s003300100908",
language = "English (US)",
volume = "11",
pages = "2319--2331",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Superparamagnetic iron oxide contrast agents

T2 - Physicochemical characteristics and applications in MR imaging

AU - Wang, Y. X.J.

AU - Hussain, S. M.

AU - Krestin, G. P.

PY - 2001/11/20

Y1 - 2001/11/20

N2 - Superparamagnetic iron oxide MR imaging contrast agents have been the subjects of extensive research over the past decade. The iron oxide particle size of these contrast agents varies widely, and influences their physicochemical and pharmacokinetic properties, and thus clinical application. Superparamagnetic agents enhance both T1 and T2/T2* relaxation. In most situations it is their significant capacity to reduce the T2/T2* relaxation time to be utilized. The T1 relaxivity can be improved (and the T2/T2* effect can be reduced) using small particles and T1-weighted imaging sequences. Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80-150 nm); SHU 555A (i.e. Resovist, mean diameter 60 nm)]. Smaller iron oxide particles are selected for lymph node imaging [AMI-227 (i.e. Sinerem and Combidex, diameter 20-40 nm)], bone marrow imaging (AMI-227), perfusion imaging [NC100150 (i.e. Clariscan, mean diameter 20 nm)] and MR angiography (NC100150). Even smaller monocrystalline iron oxide nanoparticles are under research for receptor-directed MR imaging and magnetically labeled cell probe MR imaging. Iron oxide particles for bowel contrast are coated with insoluble material, and all iron oxide particles for intravenous injection are biodegradable. Superparamagnetic agents open up an important field for research in MR imaging.

AB - Superparamagnetic iron oxide MR imaging contrast agents have been the subjects of extensive research over the past decade. The iron oxide particle size of these contrast agents varies widely, and influences their physicochemical and pharmacokinetic properties, and thus clinical application. Superparamagnetic agents enhance both T1 and T2/T2* relaxation. In most situations it is their significant capacity to reduce the T2/T2* relaxation time to be utilized. The T1 relaxivity can be improved (and the T2/T2* effect can be reduced) using small particles and T1-weighted imaging sequences. Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80-150 nm); SHU 555A (i.e. Resovist, mean diameter 60 nm)]. Smaller iron oxide particles are selected for lymph node imaging [AMI-227 (i.e. Sinerem and Combidex, diameter 20-40 nm)], bone marrow imaging (AMI-227), perfusion imaging [NC100150 (i.e. Clariscan, mean diameter 20 nm)] and MR angiography (NC100150). Even smaller monocrystalline iron oxide nanoparticles are under research for receptor-directed MR imaging and magnetically labeled cell probe MR imaging. Iron oxide particles for bowel contrast are coated with insoluble material, and all iron oxide particles for intravenous injection are biodegradable. Superparamagnetic agents open up an important field for research in MR imaging.

KW - Contrast agent

KW - Iron oxide

KW - MR imaging

KW - Superparamagnetism

UR - http://www.scopus.com/inward/record.url?scp=0034753215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034753215&partnerID=8YFLogxK

U2 - 10.1007/s003300100908

DO - 10.1007/s003300100908

M3 - Article

C2 - 11702180

AN - SCOPUS:0034753215

VL - 11

SP - 2319

EP - 2331

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 11

ER -